Nabriva Therapeutics PLC (NBRV)
1.46
-0.17
(-10.43%)
USD |
NASDAQ |
Jun 02, 16:00
Nabriva Therapeutics Net Income (Quarterly): -8.70M for March 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2023 | -8.70M |
December 31, 2022 | -22.78M |
September 30, 2022 | -11.51M |
June 30, 2022 | -11.07M |
March 31, 2022 | -11.82M |
December 31, 2021 | -13.06M |
September 30, 2021 | -10.65M |
June 30, 2021 | -11.75M |
March 31, 2021 | -13.98M |
December 31, 2020 | -17.83M |
September 30, 2020 | -12.95M |
June 30, 2020 | -15.44M |
March 31, 2020 | -23.26M |
December 31, 2019 | -23.04M |
September 30, 2019 | -17.80M |
June 30, 2019 | -21.71M |
March 31, 2019 | -20.22M |
December 31, 2018 | -30.82M |
September 30, 2018 | -52.82M |
Date | Value |
---|---|
June 30, 2018 | -17.79M |
March 31, 2018 | -13.34M |
December 31, 2017 | -22.26M |
September 30, 2017 | -22.27M |
June 30, 2017 | -14.60M |
March 31, 2017 | -15.22M |
December 31, 2016 | -15.19M |
September 30, 2016 | -14.00M |
June 30, 2016 | -12.10M |
March 31, 2016 | -13.60M |
December 31, 2015 | -23.12M |
September 30, 2015 | -8.213M |
June 30, 2015 | -5.897M |
March 31, 2015 | -9.731M |
December 31, 2014 | -4.097M |
September 30, 2014 | -4.505M |
June 30, 2014 | -2.183M |
March 31, 2014 | -3.437M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-52.82M
Minimum
Sep 2018
-8.70M
Maximum
Mar 2023
-18.45M
Average
-16.61M
Median
Net Income (Quarterly) Benchmarks
Avadel Pharmaceuticals PLC | -30.78M |
Medtronic PLC | 1.179B |
Jazz Pharmaceuticals PLC | 69.42M |
Iterum Therapeutics PLC | -9.889M |
Mallinckrodt PLC | -249.30M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 7.59M |
Total Expenses (Quarterly) | 16.06M |
EPS Diluted (Quarterly) | -2.72 |
Enterprise Value | 3.418M |
Gross Profit Margin (Quarterly) | 41.53% |
Profit Margin (Quarterly) | -114.6% |
Earnings Yield | -1.32K% |
Normalized Earnings Yield | -1315.07 |